Treating fatty liver disease by modulating mitochondrial pyruvate metabolism. Issue 3 (18th April 2017)

• Record Type: Journal Article
• Authors: Colca, Jerry R.; McDonald, William G.; McCommis, Kyle S.; Finck, Brian N.
• Is Part Of: Hepatology communications. Volume 1:Issue 3(2017)
• Page Start: 193
• Page End: 197
• Publication Date: 2017-04-18
• Subjects: Hepatology -- Periodicals; Liver -- Diseases -- Periodicals; Liver Diseases; Gastroenterology; Periodicals; Fulltext; Internet Resources; Periodicals; 616.36
• DOI: 10.1002/hep4.1036
• Languages: English
• ISSNs: 2471-254X

Abstract

Abstract : Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. ( Hepatology Communications 2017;1:193‐197)